Sign up
Pharma Capital

Summit Therapeutics hugely excited after big DMD ‘breakthrough’

Glyn Edwards, chief executive of Summit Therapeutics PLC (LON:SUMM,NASDAQ:SMMT), adds a bit of extra detail to their announcement this week around the interim data for their treatment for Duchenne Muscular Dystrophy (DMD).

The interim results for the PhaseOut study revealed a “statistically significant and meaningful” reduction in muscle damage in patients taking the company’s treatment, ezutromid.

''We're really pleased ... I wouldn't say we're surprised as we believe in the technology and we've been really hopeful that we're going to be able to make a huge impact on this really nasty disease that affects so many young men''.

 

View full SUMM profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.